EGFR and non-small cell lung carcinoma: In contrast, another phase II trial to study osimertinib in EGFR exon 20 insertion NSCLC (LU17-19) reported a 0% RR and median PFS of 3.5 months in 15 EGFR exon 20 insertion patients [39].